期刊文献+

Raclopride在帕金森病PET中的应用 被引量:1

Application of raclopride PET in Parkinson's disease
下载PDF
导出
摘要 帕金森病是发生于中年以上的中枢神经系统的变性疾病,由于多巴胺产生不足,引起多巴胺D2受体功能异常。Raclopride(雷氯必利)对中枢神经系统D2受体具有高度的选择性和亲和力,是研究D2受体分布的理想示踪剂。11C-raclopridePET可在分子水平直观地显示D2受体的分布、密度及变化情况,对帕金森病的病情分析、序列运动的多巴胺机制分析、运动波动合并症的机制分析、药物作用机制分析、外科治疗的机制分析等方面具有重要意义。 Parkinson's disease( PD ) is a kind of degenerative disease afflicting middle-aged and older people, accompanied by abnormal D2 receptor function resulted from dopamine deficiency. Raclopride is an ideal tracer because of its high selectivity and affinity to D2 receptor. 11C-raclopride PET can directly show the distribution and density of D2 receptor on molecular level that it's of great importance in the analysis of the illness state and dopamine mechanism of sequential movement, movement-fluctuation complication, medicine and surgical therapy.
作者 闫卫红
出处 《国外医学(放射医学核医学分册)》 2005年第1期27-29,共3页 Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
关键词 雷氯必利 帕金森病 受体 多巴胺D2 正电子发射型体层显像 raclopride Parkinson's disease receptor,dopamine D2 position emission tomography
  • 相关文献

参考文献16

  • 1Hirvonen J, Aaho S, Lumme V, et al. Measurement of striatal and thalamic dopamine D2receptor binding with ^11C-raclopfide [J]. Nucl Med Commun, 2003, 24(12): 1207-1214.
  • 2Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with ^11C-raclopfide and positron emission tomography[J]. Ann Neurol, 1992, 31(2): 184-192.
  • 3Rinne JO, Laihinen A, Rinne UK, et al. D2 receptor changes during the progression of early Parkinson's disease[J]. Mov Disord, 1993, 8(2): 134-138.
  • 4Rinne JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [^11C]raclopride[J]. J Neurol Sci, 1995, 132(2): 156-161.
  • 5Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias[J]. Neurology, 1997,49(3): 717-723.
  • 6Sawle GV, Playford ED, Brooks DJ, et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism: Diagnostic implications of the D2 receptor status[J]. Brain, 1993, 116 (4): 853-867.
  • 7Antonini A, Schwarz J, Oertel WH, et al. long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease:a study with positron emission tomography and [11C]raclopride[J]. Mov Disord, 1997, 12(1): 33-38.
  • 8Goerendt IK, Messa C, Lawrence AD, et al. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study[J]. Brain, 2003, 126(2): 312-325.
  • 9Ouchi Y, Yoshikawa E, Futatsubashi M, et al. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomog-raphy study[J]. J Cereb Blood Flow Metab, 2002, 22(6): 746-752.
  • 10Tedroff J, Pedersen M, Aquilonius SM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C] raclopride displacement and PET [J]. Neurology, 1996, 46(5): 1430-1436.

同被引文献14

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部